Cell surface antigen and molecular targeting in the treatment of hematologic malignancies

Stem Cells

Volumn 20, Issue 3, 2002, Pages 215-229

  Countouriotis, Athena ^a   Moore, Theodore B ^a   Sakamoto, Kathleen M ^a,b,c  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Leukemia; Lymphoma; Molecular targeting; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; BCR ABL PROTEIN; CD45 ANTIBODY; CD45 ANTIGEN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; HUM 195; IMATINIB; MEMBRANE ANTIGEN; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; ST1 571; TOSITUMOMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANGIONEUROTIC EDEMA; ANTIBODY LABELING; ANTIGEN BINDING; BONE MARROW TRANSPLANTATION; CANCER; CELL SPECIFICITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FEVER; GENE FUSION; GENE TARGETING; HEMATOLOGIC DISEASE; HUMAN; MORBIDITY; MYALGIA; NAUSEA; PRURITUS; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0036244517     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.20-3-215     Document Type: Short Survey

References (106)

1. Monoclonal antibody-based therapies for hematologic malignancies
2. The in vivo localization of anti-Wagner osteogenic sarcoma antibody
3. Continuous cultures of fused cells secreting antibody of predefined specificity
4. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
6. The story of chronic myeloid leukaemia
7. The biology of chronic myeloid leukemia
8. Chronic myeloid leukemia
9. Monoclonal antibody therapy in lymphoid malignancies
10. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia
11. Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy
12. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
13. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon
14. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas
15. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
16. Advances in monoclonal antibody therapy of cancer
17. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines
18. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
19. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
20. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
21. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia
22. The monoclonal antibodies campath-1H and Rituximab in the therapy of chronic lymphocytic leukemia
23. Rituxan has significant activity in patients with CLL
24. Infusion-related events following rituximab therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Association with inflammatory cytokines
25. Rituximab as initial therapy for patients with low-grade non-Hodgkin's lymphoma
26. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
27. The effect of Rituximab on patients with follicular and mantle-cell lymphoma
28. Rituximab/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
29. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
30. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
31. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
32. Rituximab: Perspective on single agent experience, and future directions in combination trials
33. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusionrelated side effects and rapid blood tumor clearance
34. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
35. Monoclonal antibodies in the treatment of human B-cell malignancies
36. Consolidative immunotherapy with Rituxan in autologous stem cell transplants for follicular lymphoma is associated with molecular remissions
37. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
38. Rituximab as first-line treatment of follicular lymphoma patients with low tumor burden. Preliminary results of a phase II trial
39. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas
40. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans
41. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine
42. Campath-1 monoclonal antibodies in bone marrow transplantation
43. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
44. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
45. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
46. Objective clinical responses in patients with recurrent low-grade lymphoma treated with Campath-1H monoclonal antibody
47. Adult acute leukemia
48. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia
49. Acute leukemias
50. Prevalence and mortality rate of congestive heart failure in the United States
51. Acute myeloid leukemia
52. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
53. Expression of normal myeloid-associated antigens by acute leukemia cells
54. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
55. New developments in the treatment of acute myeloid leukemia
56. Current uses of monoclonal antibodies in the treatment of acute leukemia
57. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia
58. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): Preliminary report of a phase II study
59. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
60. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
61. Efficacy and safety of CMA-676 in patients with AML in first relapse
62. Calicheamicin gamma II: An antitumor antibiotic that cleaves double-stranded DNA site specifically
63. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients <60 and >60 years of age with AML in first relapse
64. Short-term outcomes after treatment for relapsed AML: A comparison of recent CMA-676 clinical trial data and historical control data
65. Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg, CMA-676) followed by hematopoietic stem cell transplantation
66. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
67. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high dose cytarabine combination therapy in the treatment of patients with AML
68. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
69. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
70. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
71. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
72. Human homologue of murine T200 glycoprotein
73. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia
74. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
75. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody
76. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
77. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
78. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission
79. Acute myeloid leukemia
80. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
81. Chronic myelogenous leukemia: Biology and therapy
82. STI571: Targeting BCR-ABL as therapy for CML
83. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
84. Chronic myelogenous leukaemia - New therapeutic principles
85. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells
86. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
87. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
88. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
89. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
90. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
91. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure
92. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
93. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
94. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
95. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myelogenous leukemia
96. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
97. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
98. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
99. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
100. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
101. Chronic myelogenous leukemia
102. Chronic myeloid leukemia: Current treatment options
103. Transcription factors and translocations in lymphoid and myeloid leukemia
104. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in RA-therapy resistant t(11;17)(q23;q21) APL patient